4/A: Veracyte Director Evan Jones Amends Form 4 Filing to Clarify Stock Sales

Director Evan Jones amended a previous Form 4 filing to clarify the breakdown of common stock sales executed under a Rule 10b5-1 plan.

Summary

• Evan Jones, a director of Veracyte, Inc., filed an amendment to a Form 4, initially filed on August 9, 2024, to correct the reported sale of common stock.
• The transactions occurred on August 7, 2024, and were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2024.
• The amended filing clarifies that of the 5,108 shares sold, 3,143 shares were sold directly by Jones, and 1,965 shares were sold by jVen Capital, LLC, where Jones is the sole managing member.
• The weighted average sales price for the transactions was $30.3217, with individual sale prices ranging from $30.02 to $30.73.
• Following the reported transactions, Jones directly owns 47,145 shares and indirectly owns 33,208 shares through jVen Capital, LLC.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock sales by a company insider under a pre-arranged trading plan. It doesn't convey any particularly positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.

Key Dates